TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Detection of advanced neoplasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Effectiveness for treatment of forehead lines
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Drug-induced liver injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Wrist functionality improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Range of motion (ROM) in extension and flexion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lives saved from breast cancer
Endpoint domain: Mortality/survival
Primary endpoint: Androgen and estrogen levels in antral fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Activity limitation
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Concern-related reactions to radon exposure
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Intentions to test home for radon
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Perceived importance of testing for radon
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Sum of TNSS (Total Nasal Symptom Score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Divergent thinking performance
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Total WBC count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Leukocyte subclasses count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mean mid-luteal progesterone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Days with luteal-phase basal temperatures over 98 degrees F
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: postoperative discomfort and pain scores
Endpoint domain: Adverse events/effects
Primary endpoint: skin colour
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: CS-PFP scores improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Walking economy improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: overall symptom score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: hypoglycaemia symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: hyperglycaemia symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Lung function tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composition of high density lipoproteins (HDL) in newborns
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum cholesterol level in neonates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction in vomiting episodes per week
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Reduction in binge-eating episodes per week
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Composite outcome of recurrent venous thromboembolism and major bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: 20/70 or better BCVA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stable or improved letter score (≥0-letter gain)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decline by 15 letters or more
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in necrosis of hepatocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: composite end point incidence
Endpoint domain: Mortality/survival
Primary endpoint: Severe neutropenia (CTCAE grade 3/4)
Endpoint domain: Adverse events/effects
Primary endpoint: Infections (CTCAE grade 3/4)
Endpoint domain: Adverse events/effects
Primary endpoint: Fatal infections
Endpoint domain: Adverse events/effects
Primary endpoint: Delivery of BCTs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fidelity to the protocol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Partial delivery of BCTs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Transcutaneous bilirubin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mean plasma glucose level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of time with low glucose level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean frequency of interventions for hypoglycemia
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: CVA risk
Endpoint domain: Mortality/survival
Primary endpoint: Use of gold standard treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Satisfaction with side effects
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Clinical improvement response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mycological improvement response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective symptom score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: CFS (Corneal Fluorescein Staining)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hospitalization expenses
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Pseudocyst recurrence
Endpoint domain: Mortality/survival
Primary endpoint: Physical component scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Frequency of bladder spasm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of bladder spasm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain visual analogue score of bladder spasm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: QuickDASH scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Pain during engagement and disengagement of archwires
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fetal acidosis (pH < 7.20)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in absolute MSC score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Onset of action of FEX60/PSE120
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in TSC score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of severe hypoglycaemic events
Endpoint domain: Adverse events/effects
Primary endpoint: positive predictive values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Roland Morris Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Modified Von Korff disability score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Modified von Korff pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postprandial triglyceride response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Red blood cell uptake of Ergothioneine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Satisfaction with the consultation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Increase in negative emotions
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: central venous thrombosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: EDSS increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Splenic Volume (V)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apparent Diffusion Coefficient (ADC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Attitudes towards searching for health information
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: elimination of mild glabellar lines at repose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of new pressure ulcers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gastric pH values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Interobserver agreement for Urinary Tract Dilation risk score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pmean (cmH2O)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SP-D level (μg/L)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean cumulative number of new gadolinium-enhancing lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: mean cumulative number of new T2 lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: relapse rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Gestational Diabetes (GD) development
Endpoint domain: Mortality/survival
Primary endpoint: Median weight reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage reduction in serum insulin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Peak O(2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Saphenous vein graft patency rates at 1 year post-CABG
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Major bleeding episodes during 1 year of follow-up
Endpoint domain: Adverse events/effects
Primary endpoint: Infants' growth (weight/height Z score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RMDQ score difference between Yoga Group and Control Group
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: QALY per patient-caregiver dyad
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Caregivers' incidence of depression and/or anxiety disorders
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Decrease in self-blame about eating
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Adjustment to more realistic weight loss goals
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Satisfaction with a 5% weight loss
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: 4-year biochemical relapse-free survival rate
Endpoint domain: Mortality/survival
Primary endpoint: GI toxicity symptom categories
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: urinary morbidity symptom categories
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Variability of fasting blood glucose values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: TBPI improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Restenosis rate
Endpoint domain: Adverse events/effects
Primary endpoint: BAI scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Health behavior changes
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: dysfunction
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Clearance of atorvastatin lactone (CL(M)/F)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of migraine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of migraine-like headache
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Headache severity and intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endothelium dependent/independent dilatation ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 8-OH deoxyguanosine content
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total antioxidant reactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Panic symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-operative IPSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of ropivacaine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(0-infinity) of ropivacaine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Length of nerve blockade
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite rate of major adverse cardiac events (MACE)
Endpoint domain: Adverse events/effects
Primary endpoint: Rates of change in BMC at the total hip and trochanter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Success rate of blood sample collection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Agreement interval for hemoglobin measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Agreement interval for potassium measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Symptom score at 1-year follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Superficial SSI rate
Endpoint domain: Adverse events/effects
Primary endpoint: Satisfaction scores at 3 months
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: change in liver fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Incident heart failure (HF)
Endpoint domain: Mortality/survival
Primary endpoint: Knowledge about infant crying
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Walking away during inconsolable crying
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement in general skin texture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: improvement in discoloration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: reduction of wrinkles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: NYHA class improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: NT-proBNP levels reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Diagnosis of BV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BMD loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: treatment-failure cumulative pregnancy rate
Endpoint domain: Mortality/survival
Primary endpoint: Serum folate levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Homocysteine (HCY) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: oral-cecal transit time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Improvement of ASQ score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Rizzo scale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resting heart rate reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maximal heart rate response to handgrip
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Blood pressure responses to handgrip
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: elevations of cardiac enzymes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: left ventricular wall motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean aqueous humor ceftazidime concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in endpoints
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LBP during physical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle endurance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum adalimumab concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 30-day point prevalence tobacco quit rates
Endpoint domain: Mortality/survival
Primary endpoint: SF-36 physical component summary improvement
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: HAQ improvement
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: FACIT-Fatigue improvement
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: intragastric volume increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: effusion variable
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: position of the mandibular head or the disc‐head complex
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: final maximum interincisal distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of PET/CT for detecting distant metastasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive predictive value (PPV) of PET/CT for detecting distant metastasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of comprehension of reversible sentences
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative cardiac function recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Skin elasticity and hydration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Pigmentation, erythema, and pore size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Serum N‐telopeptide concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: plasma TG levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Prevalence of pulmonary TB disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: OA blood flow velocity modifications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: self-reported perception of independence in IJ-CVLP
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: mean percentage of IJ-CVLPs performed independently
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relation between biogenic amines and food intolerance reactions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Defect severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Defect reversibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage reversibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: mean endometriosis score including adhesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean laparoscopic endometriosis score not including adhesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in heroin use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage in treatment at 16-month follow-up
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Alcohol tolerance
Endpoint domain: Adverse events/effects
Primary endpoint: Student learning and performance
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Spine bone mineral density (BMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Lower body muscle strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: ovulation inhibition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Time ready for discharge from PACU
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Analgesia satisfaction rate
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Severe pain rate
Endpoint domain: Adverse events/effects